BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET. A live webcast of the fireside chat can be accesse ...

Earnings season has begun, and I managed to find a few nuances in Tango Therapeutics (NASDAQ: TNGX ) that motivated me to take a long position via long options on thisHi, I'm Martin, I focus on maintaining a delta neutral portfolio. I want to be long/short at the same time and benefit from market volatility. I specialize in using options through which I enter and exit trades. I look for market opportunities primarily in small companies, and my search takes me into the waters of mid-sized companies as well.A ...

The next wave of targeted therapies in oncology Corporate Overview January 2025 케 TANGO Disclaimer and Safe Harbor Statement Cercain statuences in this presentation may be considered for worded boking studioned by the belate statements genedly reals of man financial and manychom and concerior per "Should", "taped","thind","tablicwled","twhesenes","twill","trucest","testimatis","spetantial","selent","revlier","revlier","rockice", or "commer", onle ngelseries of the n milinidele common cances: the Campany's e ...

Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.59%. A quarter ago, it was expected that this company would post a loss of $0.34 per share when it actually produced a loss of $0.24, delivering a surprise of 29.41%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights – Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – – Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors – – Next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, TNG456, planned to enter the ...

Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 29.41%. A quarter ago, it was expected that this company would post a loss of $0.31 per share when it actually produced a loss of $0.35, delivering a surprise of -12.90%. Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-11 ...

Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights – Dose expansion ongoing in TNG908 and TNG462 phase 1/2 clinical trials; comprehensive clinical data update for the PRMT5 program expected in 2H 2024 – – Patient enrollment is ongoing in TNG260 phase 1/2 clinical trial – – Strong cash position of $322 million as of June 30, 2024; cash runway into 2027 expected to fund clinical programs through proof-of-concept – BOSTON, Mass. – August 7, 2024 – Tango Therapeuti ...

The market expects Tango Therapeutics, Inc. (TNGX) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. Revenues are expected to be $7.39 million, down 49.4% from the year-ago quarter. Estimate revisions ahead of a company's ...